Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02968849 |
Recruitment Status :
Completed
First Posted : November 21, 2016
Last Update Posted : May 19, 2022
|
Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Sanofi
GlaxoSmithKline
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | November 16, 2021 |
Actual Study Completion Date : | November 16, 2021 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):